Nigral burden of α-synuclein correlates with striatal dopamine deficit

Movement Disorders

Volumn 23, Issue 11, 2008, Pages 1608-1612

  Kovacs, Gabor G ^a   Milenkovic, Ivan J ^a   Preusser, Matthias ^a   Budka, Herbert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

synuclein; Brain imaging; Dopamine transporter; Parkinson disease; Striatum

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; CELL INCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION FUNCTION; DIFFUSE LEWY BODY DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSTMORTEM CHANGES; SUBSTANTIA NIGRA;

EID: 53149130592     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22207     Document Type: Article

References (15)

1. Sidhu A, Wersinger C, Vernier P. α-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 2004;565:1-5.
2. Sidhu A, Wersinger C, Vernier P. Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 2004; 18:637-647.
3. Ciliax BJ, Drash GW, Staley JK, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 1999;409:38-56.
4. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003;62:1241-1253.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
6. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body conical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:852-856.
7. Parkkinen L, Soininen H, Laakso M, Alafuzoff I. α-Synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001;27:314-325.
8. Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I. Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject. Neuropathology 2005;25:304-314.
9. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005;57:82-91.
10. Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, Wakabayashi K. Relationship among α-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol 2006;65:808-815.
11. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease Brain 1999;122:1437-1448.
12. Kovacs GG, Gelpi E, Strobel T, et al. Involvement of the endosomal-lysosomal system correlates with regional pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 2007;66:628-636.
13. Kramer ML, Schulz-Schaeffer WJ. Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-1410.
14. Wersinger C, Sidhu A. Attenuation of dopamine transporter activity by α-synuclein. Neurosci Lett 2003;340:189-192.
15. Wersinger C, Jeannotte A, Sidhu A. Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein. Eur J Neurosci 2006;24:3141-3152.